Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. [electronic resource]
Producer: 20171229Description: 524-532.e2 p. digitalISSN:- 1534-4436
- Activities of Daily Living
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Asthmatic Agents -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Asthma -- drug therapy
- Biomarkers -- blood
- Cell Adhesion Molecules -- blood
- Child
- Comorbidity
- Humans
- Immunoglobulin E -- blood
- Leukocyte Count
- Middle Aged
- Omalizumab -- adverse effects
- Prospective Studies
- Quality of Life
- Surveys and Questionnaires
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.